british scientists developed experimental vaccine bowel cancer second common cause cancer deaths industrialised countries it tested first potential treatment patients advanced cancer could used eventually preventive vaccine people known genetically risk colorectal bowel cancer the cancer research campaign funded vaccines development nottingham university said yesterday the first clinical trials indicate impressive results patients imclone systems new york biotechnology company signed exclusive worldwide licensing agreement crc commercial development vaccine 105ad7 known imclone leader fastgrowing research field cancer vaccines also testing vaccines lung cancer melanoma dr lindy durrant dr adrian robbins developed 105ad7 nottingham said potential prevent bowel cancer stop disease progressing also advantage producing toxic sideeffects unlike conventional treatments the encouraging first results came tests dozen patients advanced bowel cancer published next week the crc organising larger clinical trial based nottingham 350 patients imclone carry extensive trial us even new vaccine continues perform well unlikely approved commercial treatment bowel cancer 1997 its use preventive vaccination might follow four years later there several ways researchers planning use vaccines prevent cancer one indirect approach immunising people viruses epstein barr associated certain cancers the crcimclone approach hand aimed directly tumour cells vaccine 105ad7 designed mimic particular part cell surface this primes patients immune system recognise attack cancer cells every year 28000 people uk diagnosed bowel cancer only 9000 alive five years later in us disease kills 55000 people year bowel cancer second common cause cancer death west said prof gordon mcvie crc scientific director